Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Bispecific DLL3 × CD3 T-cell engager

Tarlatamab (Specialist drug)

Brand names: Imdelltra

Tarlatamab is a bispecific T-cell-engaging antibody used in adults with advanced small-cell lung cancer that has progressed after prior chemotherapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds DLL3 on small-cell lung cancer cells and CD3 on T cells, bringing the two together so that T cells are activated to destroy the tumour cells.

Prescribing in practice

  • Cytokine release syndrome and neurological toxicity (including ICANS) can be serious, so the first doses are given with a step-up schedule and close monitoring in an appropriate care setting.
  • Patients should be monitored for an adequate period after early doses and counselled not to drive if neurological symptoms are possible.
  • Infections, cytopenias and infusion-associated reactions can occur.

Monitoring

Monitor closely for cytokine release syndrome and neurological symptoms, especially during and after the initial step-up doses, alongside blood counts and signs of infection.

Counselling the patient

  • Seek urgent help for fever, dizziness, confusion, or new weakness or difficulty speaking.
  • Arrange to stay close to the treatment centre and avoid driving during the early monitoring period as advised.
  • Report signs of infection promptly.

Evidence & guidelines

Efficacy in previously treated small-cell lung cancer was shown in a dedicated registrational trial.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways